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15 July, 2016 
Dear Dr Greenamyre, 
We wish to submit our manuscript entitled “Comparison of oscillatory activity in subthalamic 
nucleus in Parkinson’s disease and dystonia” for consideration of publishing by the 
Neurobiology of Disease.  
In this manuscript, we studied the spectral and temporal patterns of oscillatory activity of the 
local field potentials (LFPs) recorded from subthalamic nucleus (STN) in patients with 
dystonia and Parkinson’s disease (PD). It has been widely evidenced that a prominent beta 
frequency band activity in the STN of PD patients but still unclear whether such activity 
occurs in dystonic STN or not, and whether dystonia has another distinctive activity. While in 
a previously study published in the Neurobiology of Disease early this year (Wang et al, 2016. 
doi: 10.1016/j.nbd.2016.02.015.), no significant differences in both beta power and the 
coupling of beta phase to high frequency oscillation amplitude of subthalamic LFPs in 
dystonia and PD were reported. In comparison, our study shows contrary results that 
distinctive oscillatory patterns are found over both low frequency (5-10 Hz) and beta 
frequency (11-32 Hz) bands. To evaluate the oscillatory activities of LFPs, we used power 
spectra to specify oscillations in frequency domain and Lempel-Ziv complexity, which is 
unaffected to the amplitude of signal, to illustrate the dynamic temporal patterns in the time 
series. Moreover, a dystonic case with medication treatment in our data shows similar patterns 
of LFPs as in untreated PD rather than dystonia. This gives a hint that such patterns may be 
more tightly locked to pharmacological states than disease pathology per se.      
Because of the differences in medication and recording states of these studies, our results are 
likely to be of great interest to the researchers, clinicians and scientists who read your journal 
and consider future studies in this field.  
We confirm that this work is original and not currently under consideration for publication 
elsewhere. It has been approved by all authors to submit to the journal. We would like to 
recommend Dr Manuel Alegre, Dr Christian Moll, Dr Kai Bötzel, Prof Peter Silburn and Prof 
Alireza Gharabaghi as reviewers. If you may consider, please find their contact information 
following the letter.  
Thank you for receiving and considering of this manuscript. We appreciate your time and 
look forward to your response. 
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Xinyi Geng 
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Dear Professor Greenamyre, 
Thank you for affording us the opportunity to revise our manuscript. We have 
addressed the reviewers point below and highlighted changes in the main manuscript. 
 
Reviewer #2: The revised manuscript "Comparison of oscillatory activity in subthalamic 
nucleus in Parkinson's disease and dystonia" by Geng and colleagues addresses some of my 
concerns regarding the original version, however, some of my major comments were not 
addressed sufficiently. 
1. LZC - The relation of this measure to oscillations is non-straightforward (see for 
example Aboy et al., IEEE, 2006) and does not merely describe the beta oscillation in an 
"amplitude independent" manner. Thus, it should be dropped (my recommendation) or 
explained very explicitly and the interpretation of its results clearly stated, especially as this 
manuscript is not intended for engineers or physicists. 
We would rather keep some mention of the LZC results as they help limit the confound due 
to signal amplitude variance between subjects and sides due to any slight differences in the 
targeting of electrodes.  
We have now revised and included the description of the use of LZC as follows:  
Methods: “Power spectra characterise average distributions of signal variance over frequency, 
but do not fully capture temporal patterns in the time series. Lempel-Ziv complexity (LZC) 
measures the random level of a time series by evaluating the regularity/randomness and 
numbers of repeats in the binary sequence. For a totally random time series, the patterns of 
the sequence are theoretically unpredictable and there are a higher number of different 
subsequences. The number of subsequences is limited for regular oscillations and the LZC 
value is lower compared to more random signals, like white noise. The LZC is generally 
independent of the amplitude scaling as the signal is converted to binary sequences (Ziv and 
Lempel. 1977; Zhang et al. 2001; Gomez et al. 2011). Hence, it is relatively immune to LFP 
signal variations due to minor differences in surgical targeting, and has previously been 
shown to be negatively correlated with the strength of beta band synchronisation (Chen et al. 
2010).  
The pre-processed signals were band-pass filtered over low frequency, low beta and high beta 
(band-pass centred on the peak in each band ± 3Hz wide) and a high gamma band over 60-
140 Hz (band-pass centred on the peak ± 10Hz wide). In the absence of a peak the frequency 
in the low frequency and beta bands was taken to be that of the peak in the respective band in 
the group average. The individual neural oscillations of STN LFPs were converted into a 
binary sequence by thresholding using the median value of the amplitude of the neural 
oscillations as the threshold and the LZC applied on every 1 second epoch and averaged (Ziv 
and Lempel.1977; Chen et al. 2010).  
The principle of LZC is to measure the number of distinct patterns in a 0-1 sequence by 
scanning the sequence from left to right and counting the number of patterns every time a 
new one occurs. The LZC was computed with the following steps: 
(1) Initialise the sequences S and Q as two subsequences of the digitalized time series, 
Response to Reviews
          . SQ is the concatenation of S and Q and SQπ is defined as SQ with the 
last symbol being deleted. At the beginning, SQπ =    and the counting number of 
distinct pattern CN =1.     
(2) Scan the unprocessed sequence,           , by removing the first symbol and 
adding it in Q. If Q belongs to SQπ, then Q is not a new pattern, then append the next 
unprocessed symbol in Q and repeat the judgement until the renewed Q does not 
belong to SQπ, then the Q is a new pattern.  
(3) Increase the counting number CN by one. The Q is appended to S and then reset to 
empty. Update the unprocessed sequence and repeat from step (2) until Q is the last 
character.  
(4) The LZC is then derived by the formula:  
    
  
         
 
where N is the length of the sequence.  
 
Discussion:  
“Dynamics of activity 
The LZC characterizes the complexity of a given signal by measuring the repeatable patterns 
in the signal, and is derived by counting the number of the new subsequences (Ziv and 
Lempel. 1977; Zhang et al. 2001; Aboy et al. 2006). The LZC reflects the rate of new 
patterns in the sequence, which is related to the randomness and predictability of the signal, 
and is also influenced by the level and distribution of the noise in the signal (Aboy et al. 
2006). The LZC is low when the signal is regular and predictable, and it is high when the 
signal is random and less predictable. For example, the LZC decreases when the EEG signal 
becomes synchronised with high-amplitude slow waves (Andrillon et al. 2016), and is a 
robust measure reflecting the decrease of neural complexity of spontaneous EEG during 
general anesthesia (Schartner et al. 2015). This is able to accurately track the level of 
consciousness in patients and health subjects under anesthesia and during sleep (Zhang et al. 
2001; Andrillon et al. 2016). In PD patients, resting state MEG signals show less complexity 
than in control subjects (Gomez et al. 2011). STN local field potentials in PD patients also 
have reduced complexity, and there is significant negative correlation between the 
complexity of these signals, assessed using LZC, and akinesia-rigidity (Chen et al. 2010). 
The LZC may therefore be considered a useful tool for capturing neural dynamics.” 
The following references have also been added. 
Aboy M, Hornero R, Abásolo D, et al. Interpretation of the Lempel-Ziv complexity measure in the 
context of biomedical signal analysis. IEEE Trans Biomed Eng 2006;53: 2282-2288. 
Andrillon T, Poulsen AT, Hansen LK, et al. Neural Markers of Responsiveness to the Environment in 
Human Sleep. J Neurosc 2016;36: 6583-6596. 
Gómez C, Olde Dubbelink KT, Stam CJ, et al. Complexity Analysis of Resting-State MEG Activity 
in Early-Stage Parkinson's Disease Patients. Ann Biomed Eng 2011;39: 2935-2944. 
Schartner M, Seth A, Noirhomme Q, et al. Complexity of Multi-Dimensional Spontaneous EEG 
Decreases during Propofol Induced General Anaesthesia. PloS One 2015;10. 
Zhang XS, Roy RJ, Jensen EW. EEG complexity as a measure of depth of anesthesia for patients. 
IEEE Trans Biomed Eng 2001;48: 1424-1433. 
Ziv J and Lempel A. Universal algorithm for sequential data compression. IEEE Trans Inform Theory 
1977;23: 337-343. 
 
2. Single case report - The authors have made some changes to the manuscript but have 
left the conclusion based on a speculation regarding this single case report as a very 
significant result and specifically left it as the main conclusion in the abstract. It should be 
dropped from the abstract and preferably also from the discussion.  
Conclusions related to this single case have now been removed from the abstract and from 
the ‘conclusion’ section at the end of the Discussion. 
 
 
Reviewer #3: It is indeed unfortunate that the issue of stereotactic reconstruction of the 
recording sites could not be addressed, as the referee considers this important for the correct 
interpretation of the data. To the credit of the authors, this caveat is now acknowledged in the 
manuscript. The other issues have been adequately addressed. I have no further concerns. 
We share the reviewer’s disappointment with respect to the available imaging, but are pleased 
that the reviewer feels that the revised discussion on this topic reproduced below helps 
highlight this study limitation. 
“Recordings from the patient groups were derived from different centres which raises the 
possibility that there were subtle differences in the targeting. We were unable to explore this 
issue further due to the generally thick acquisition slices made during post-operative imaging 
in the patients with dystonia and the unavailability of some of the imaging in some of the 
archival patients. Targeting variance may increase the variance between subjects as LFP 
amplitude is dependent on the distance from the generator. Our spectral normalization and 
use of the LZC help address this issue. In Supplementary Methods we also include the 
spectral results when we average across all electrode contacts so as to further limit the effects 
of any potential small systematic variation in the targeting between the centres, although such 
averaging has the drawback that spatial resolution is limited and we can only ascribe those 
spectral findings to the STN area. Nevertheless, the differences between conditions in data 
from the broader STN area were similar to those presented in the main results.” 
Highlights 
 
» Spectral power and temporal patterns of the oscillation in subthalamic nucleus in 
dystonia and Parkinson’s disease are distinctive.  
» Dystonic case on aripiprazole shows association with a similar spectral pattern in 
the subthalamic nucleus as in untreated patients with Parkinson’s disease. 
» The same region can be involved in different patterns of circuit dysfunction that 
may explain the paradox whereby functional surgical approaches to the same 
target can improve different conditions. 
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Abstract 
Objectives. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been successfully used 
to treat both Parkinson’s disease (PD) and dystonia. Local field potentials (LFPs) recorded from the 
STN of PD patients demonstrate prominent beta frequency band activity. It is unclear whether such 
activity occurs in the STN in dystonia, and, if not, whether dystonia has another distinctive neural 
population activity in the STN. Methods. Twelve patients with PD, and eight patients with dystonia 
underwent DBS electrode implantation targeting the STN. Seven dystonia patients were off medication 
and one was on aripiprazole and clonazepam. LFPs were recorded from the DBS electrodes in PD in the 
on/off medication states and in dystonia. Power spectra and temporal dynamics measured by the with 
Lempel-Ziv complexity of the LFPs were compared among these states. Results. Normalised power 
spectra and Lempel-Ziv complexity of subthalamic LFPs differed between dystonia off and PD on/off, 
and between PD off and on over the low frequency, beta and high gamma bands. Patients with dystonia 
and off medication had lower beta power but higher low frequency and high gamma power than PD. 
Spectral power in the low beta frequency (11-20 Hz) range was attenuated in medicated PD. Conclusion. 
The results suggest that dystonia and PD are characterized by different patterns of oscillatory activities 
even within the same nucleus, and exaggerated beta activity may relate to hypo-dopaminergic status. 
Keywords: Subthalamic nucleus; oscillation; dystonia; Parkinson’s disease. 
Abbreviations: STN:  subthalamic nucleus; PD: Parkinson’s disease; LFPs: local field potentials; DBS: 
deep brain stimulation; GPi: globus pallidus internus; LZC: Lempel-Ziv complexity; BFMDRS: Burke-
Fahn-Marsden Dystonia Rating Scale; CDQ-24: Craniocervical Dystonia Questionnaire; UPDRS: 
Unified Parkinson’s disease rating scale.  
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Introduction 
Evidence is accruing that there is synchronised oscillatory activity in some of the basal ganglia nuclei 
that typically occurs in the beta frequency band in Parkinson’s disease (PD) and in the theta frequency 
band in dystonia (López-Azcárate et al. 2010).  It has been widely reported that the local field potentials 
(LFPs) from the subthalamic nucleus (STN) exhibit excessive beta activity in patients with PD (Brittain 
and Brown. 2014). Such activity is suppressed by treatment with levodopa and by deep brain stimulation 
(DBS) of the STN (Eusebio et al. 2011; Kühn et al. 2005; Whitmer et al. 2012). Moreover, therapy 
induced suppression of beta levels correlates with the degree of induced clinical improvement, 
particularly with changes in bradykinesia and rigidity (Kühn et al. 2005; Kühn et al. 2008a; Kühn et al. 
2009; Özkurt et al. 2011; Ray et al. 2008; van Wijk  et al. 2016; Weinberger  et al. 2006; Zaidel et al. 
2010).   
In contrast, in patients with dystonia, oscillatory activity over a low frequency band (4-10Hz) has been 
frequently reported from the globus pallidus internus (GPi) (Foncke et al. 2007; Lee et al. 2013; Moll et 
al. 2014; Silberstein et al. 2003; Weinberger et al. 2011). This low frequency activity in GPi is coherent 
with the EMG of dystonic muscles (Chen et al. 2006a; Liu et al. 2006; Sharott et al. 2008). Moreover, it 
is suppressed during effective DBS of the same nucleus (Barow et al. 2014). Dystonia patients do not 
generally show elevated beta activity in the GPi (Silberstein et al. 2003; Weinberger et al. 2011), unless 
treated with the monoamine vesicle depletor tetrabenazine (Kühn et al. 2008b) or in some patients with 
secondary dystonia (Whitmer et al. 2013). 
However, as most of the data in patients with PD and dystonia come from recordings in different sites 
doubt remains as to whether spectral changes are site, phenotype or disease specific. GPi can be a DBS 
target for both dystonia and PD, and case series contrasting recordings from the GPi in these two 
diseases are concordant and support the existence of discrete spectral patterns along the lines of those 
described above (Silberstein et al. 2003; Weinberger et al. 2011). More recently, STN, a classical DBS 
target in PD, has been used as a stimulating target to treat dystonia (Chou et al. 2005; Kleiner-Fisman et 
al. 2007; Ostrem et al. 2011 and 2013). However, where the subthalamic nucleus is concerned there is 
only one case series contrasting the LFP patterns in patients with dystonia and PD, and this suggested no 
difference in the spectral pattern of local field potentials between the two diseases (Wang et al. 2016). 
This would imply that any disease difference present at the level of the globus pallidus is local and not a 
feature of the wider interconnected circuits of the basal ganglia. Yet a microelectrode study and a case 
report describing findings in the STN point to a difference between these in dystonia and PD also within 
this nucleus (Schrock et al. 2009; Neumann et al. 2012). Given these contrasting results at the level of 
STN we felt it important to further investigate the spectral patterns of the STN LFP in dystonia and PD. 
(Neumann et al. 2012). We hypothesised that low frequency and beta band activities will differentially 
characterize the two disorders, even when recordings are made from the same site. In addition, we tested 
whether high gamma activity in the STN, previously postulated to be prokinetic, might be elevated in 
dystonia (Brown. 2003). 
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Material and methods 
Subjects and surgery 
All patients gave written informed consent to take part in this study, which was agreed by the local 
ethics committees. Eight patients with dystonia which had treatment failures with botulinum toxin 
(Table 1), underwent DBS electrode implantation in Tian-Tan Hospital, Capital Medical University, 
Beijing, China. Seven patients with dystonia underwent bilateral STN implantation and one with 
bilateral STN and GPi implantation, although only STN recordings are included in this study. Archival 
data from twelve subjects with PD were also analysed (Table 1); seven who underwent surgery at the 
John Radcliffe Hospital, Oxford University, Oxford, UK and five who underwent surgery at the 
National Hospital for Neurology and Neurosurgery or Kings College Hospital, London. Six of these 
patients with PD have previously been reported (Anzak et al. 2016). 10/12 patients with PD underwent 
bilateral STN implantation, one underwent unilateral STN and thalamus implantation, and one unilateral 
STN implantation only.  The two groups did not differ in age (unpaired t-test, p=0.159). All patients 
underwent evaluation for motor impairments using respective clinical scales, the Unified Parkinson’s 
Disease Rating Scale part III – motor exam under on/off medication state for PD patients, and Burke-
Fahn-Marsden Dystonia Rating Scale or Craniocervical Dystonia Questionnaire for dystonia patients 
(Muller et al. 2004; Susatia et al. 2010). The L-dopa equivalent dose in PD groups was calculated based 
on conversion factors in a previous report (Tomlinson et al. 2010).  
The procedures for STN targeting and DBS electrode implantation have been previously reported (Chou 
et al. 2005; Foltynie and Hariz, 2010). The STN was localized on the fused pre-operative frameless 
magnetic resonance (MR) and framed computed tomography (CT) images. The electrodes were targeted 
at the dorsolateral area of the STN in both groups. The targets were calculated and determined using the 
Frame link planning station (Medtronic, Minneapolis, MN, USA). The DBS electrodes were Medtronic 
3389 (Medtronic, Minneapolis, MN, USA) with four platinum-iridium cylindrical surface contacts. Each 
contact was 1.27mm in diameter and 1.5mm in length, and separated by 0.5mm. The most caudal 
contact was contact 0 and the most rostral contact 3. Subjects had local anesthesia and were awake 
during the operation to allow for the intraoperative evaluation of stimulation effects. The final 
positioning of the electrode was selected to maximize clinical improvements and, in particular, minimize 
side-effects during intra-operative stimulation (Starr. 2002). The placement of DBS electrodes was 
confirmed with fused post-operative images and pre-operative MR images on the same software as for 
pre-operative planning.  
Recording 
Patients of both groups were recorded from externalized electrode leads while sitting at rest post-
operatively 1-3 (mean 2) days following surgery in dystonia and 2-5 (mean 3) days in PD. Patients were 
not instructed to suppress any involuntary movement but were asked to avoid voluntary movement 
during recording. In the dystonia patients, case d8 was treated with clonazepam and aripiprazole during 
recording from the externalised electrode. Case d4 had a history of treatment with haloperidol and 
tiapride but ceased these two months before surgery. All datasets in dystonia were acquired at the 
Department of Neurosurgery, Beijing Tian-Tan Hospital, Capital Medical University, Beijing, China. In 
figure 1 the dystonia off group refers to the seven cases d1 to d7, and dystonia on refers to case d8, the 
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only dystonia patient on medication at the time of recording. In the PD group, all patients were recorded 
in both on and off medication conditions, using medication as prescribed preoperatively.  
In dystonia patients, bipolar LFPs were recorded from the adjacent four contacts (contact pairs: 01, 12, 
23) of each DBS electrode. The signals were amplified, notch filtered to remove 50Hz line noise, band-
pass filtered over 1-500Hz using a Digitimer Amplifier (Model D360, Digitimer Ltd., Hertfordshire, UK) 
and recorded with a sampling frequency of 2 kHz using a CED 1401 (Cambridge Electronic Design, 
Cambridge, UK).  
In PD patients LFPs were recorded monopolarly with respect to a linked earlobe reference using a 
TMSiporti amplifier (TMS international) and its respective software. Recordings were band-pass filtered 
between 0.5 and 500 Hz and sampled at 2048 Hz. Monopolar recordings of LFPs were subsequently 
converted off-line to a bipolar montage between adjacent contacts (three bipolar channels per side) to 
limit the effects of volume conduction from distant sources. Line noise artefacts at 50 Hz and 100 Hz 
were removed using notch filters.  
Signal processing 
Signals were down-sampled to 1 kHz and pre-processed with bandpass filtering over 3-45 Hz and 60-
140 Hz respectively. Signal processing, data analysis and statistical analysis were performed offline with 
scripts developed in MATLAB (MathWorks Inc., Natick, MA, USA). A continuous 50 seconds sample, 
free of artefacts signals, was selected from one bipolar channel on each side for analysis in each subject 
(details of channel selected in Table 1).  The channel was selected for further processing on the basis of 
intra-operative testing and post-operative clinical programming, and if recording quality and artefact 
free data were insufficient at that channel an adjacent one was chosen. 
Spectra analysis  
Signals were bandpass filtered between 3-45 Hz and 60-140 Hz and then z-transformed to reduce the 
variance between subjects due to surgical targeting and recording. Power spectral density was calculated 
using the Welch’s method (Shimanmoto et al. 2013; Welch. 1967) with 1 second sliding-window, 0.5 
seconds overlap and 2048 points. T-tests were introduced for statistical comparison between groups. The 
normalised power spectra from the dystonia and PD groups were compared every 0.5 Hz over 3-45 Hz 
and 60-140 Hz. To allow for multiple comparisons across frequencies we opted for conservative criteria 
for significance; three or more consecutive bins with p<0.001. Moreover, to eliminate the effects of 
frequency variance, spectra were realigned to the frequency of peak power over 5-10 Hz, 11-32 Hz and 
60-140 Hz respectively for statistical analysis. Note that dystonia case d6 was excluded in assessments 
of the high gamma band (60-140 Hz) due to broadband noise contaminating the observed frequencies. 
Note also that dystonia case d8 on aripiprazole was only included in group comparison in figure 1 as a 
single case, and excluded in the realigned spectra comparison between dystonia off medication and PD 
on/off medication groups in figure 2.   
Dynamic analysis 
Power spectra characterise average distributions of signal variance over frequency, but do not fully 
capture temporal patterns in the time series. Lempel-Ziv complexity (LZC) measures the random level 
of a time series by evaluating the regularity/randomness and numbers of repeats in the binary sequence. 
For a totally random time series, the patterns of the sequence are theoretically unpredictable and there 
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are a higher number of different subsequences. The number of subsequences is limited for regular 
oscillations and the LZC value is lower compared to more random signals, like white noise. The LZC is 
generally independent of the amplitude scaling as the signal is converted to binary sequences (Ziv and 
Lempel. 1977; Zhang et al. 2001; Gomez et al. 2011). Hence, it is relatively immune to LFP signal 
variations due to minor differences in surgical targeting, and has previously been shown to be negatively 
correlated with the strength of beta band synchronisation (Chen et al. 2010).  
The pre-processed signals were band-pass filtered over low frequency, low beta and high beta (band-
pass centred on the peak in each band ± 3Hz wide) and a high gamma band over 60-140 Hz (band-pass 
centred on the peak ± 10Hz wide). In the absence of a peak the frequency in the low frequency and beta 
bands was taken to be that of the peak in the respective band in the group average The individual neural 
oscillations of STN LFPs were converted into a binary sequence by thresholding using the median value 
of the amplitude of the neural oscillations as the threshold and the LZC applied on every 1 second epoch 
and averaged (Ziv and Lempel.1977; Chen et al. 2010).  
The principle of LZC is to measure the number of distinct patterns in a 0-1 sequence by scanning the 
sequence from left to right and counting the number of patterns every time a new one occurs. The LZC 
was computed with the following steps: 
(1) Initialising the sequences S and Q as two subsequences of the digitalized time series, 
          . SQ is the concatenation of S and Q and SQπ is defined as SQ with the last symbol 
being deleted. At the beginning, SQπ =    and the counting number of distinct pattern CN =1.     
(2) Scanning the unprocessed sequence,           , by removing the first symbol and adding in Q. 
If Q belongs to SQπ, then Q is not a new pattern, then append the next symbol in Q and repeat 
the judgement until the renewed Q does not belong to SQπ, then the Q is a new pattern.  
(3) Increasing the counting number CN by one. Q is appended to S and then reset to empty. Update 
the unprocessed sequence and repeat step (2) until Q is the last character.  
(4) The LZC is then derived by the formula:  
    
  
         
 
where N is the length of the sequence.  
 
Results  
Different spectral characteristics in dystonia and PD  
Examples of time-frequency spectra of LFPs recorded from electrodes targeting the STN are shown for 
a dystonic patient off medication, and for case d8 with dystonia but on clonazepam and aripiprazole, and 
for an exemplar PD patient recorded on and off medication (Supplementary figure 1). The normalised 
power spectra densities of 14 sides from 7 dystonia off medication patients and 2 sides from 1 on 
medication patient, together with 22 sides from 12 PD on/off medication patients are shown individually 
and averaged within groups in figure 1. Distinct spectral power peak was found in the beta band only in 
PD off and on groups and in the dystonia case d8 on clonazepam and aripiprazole, while elevated low 
frequency power and high gamma oscillation were found in the dystonia off group. Contiguously 
significant differences were found over 5-7 Hz between power spectra in dystonia off and PD on/off 
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groups (two-sample unpaired t-tests, p<0.001 in each of 3 and 5 contiguous bins respectively); over 
16.5-18 Hz between dystonia off and PD off group (p<0.001 in each of 3 contiguous bins) and over 
96.5-99.5 Hz between dystonia off and PD on/off groups (p<0.001 in each of 6 contiguous bins). Paired 
t-tests suggested a low beta power decrease in PD on compared to off state (p<0.001) but this did not 
reach our criteria for significance as it involved only one isolated bin. Moreover, the averaged spectral 
power over 24-30 Hz was significantly higher in dystonia case d8 on medication compared to dystonia 
off group (two-sample unpaired t-tests, p<0.001 in each of 9 bins) while the low frequency power 
decreased over 5-10 Hz (not significant).  The significant differences between power spectra reported 
above were also present when all recording channels were separately averaged in dystonia (n=16 sides, 
48 channels) and PD on/off medication (n=22 sides, 66 channels) and compared between the three 
groups (supplementary figure 2). This underscores that differences were not due to a bias in channel 
selection.      
Comparison of realigned peak power in dystonia and PD 
The frequency of spectral peaks varied among subjects. Peaks over the 5-10 Hz range had a mean 
frequency of 7.3 ± 1.5 Hz (mean ± SD) and 92 ± 8.6 Hz over the 60-140 Hz range in the dystonia off 
group, while those over the 11-32 Hz ranges had mean frequencies of 17.3 ± 6 Hz in the PD off group. 
Although spectral peaks in the PD off group were commonest in the low beta band and centred around 
17 Hz, two sides of one PD patient off medication demonstrated peaks only in the upper beta band. This 
variability might lead to an under-estimate of the difference between patient groups so power spectra 
were therefore separately re-aligned to the maximum value in absolute power spectra from a given 
electrode within the low frequency and whole beta band ranges (figure 2). This procedure exaggerated 
the differences between the patient groups over the 5-10 Hz, 11-32 Hz and 60-140 Hz ranges, 
particularly within the beta band in which peak frequency variation was greatest (figure 2). Unpaired t-
tests showed a significant difference between dystonia off and PD on/off states over the central 
frequencies (p<0.001 in each of at least 5 contiguous bins). The findings were similar if only peaks in 
the low beta band were selected for re-alignment before averaging (data not shown).  
Dynamic analysis in dystonia and PD 
LZC is a nonlinear dynamic analysis that provides a complexity measure of the temporal pattern of 
neural oscillations, and is not directly influenced by the amplitude scaling of the signal. Significant 
differences (figure 3) were found in LZC between dystonia off and PD on/off medication groups over 
low frequency (F (2, 55) = 21.4, p < 0.0001, one-way ANOVA), the low beta band (F (2, 55) = 104.4, p 
< 0.0001, one-way ANOVA) and the high gamma band F(2, 53)=316.3, p<0.0001, ANOVA).  The LZC 
over the 5-10 Hz and 60-140 Hz bands in dystonia off condition was significantly lower than in the PD 
on/off groups (t-tests, p<0.001 in both conditions). The LZC in the low beta band was significantly 
higher in dystonia than in PD on/off groups (t-tests, p<0.001 in both conditions). Medicated PD also had 
a higher LZC in the low beta band compared to PD off state (t-test p<0.005). 
 
Discussion  
By comparing LFPs recorded postoperatively from electrodes targeting STN in patients with dystonia 
and PD, we have demonstrated significant differences in both spectral power amplitude and dynamic 
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oscillatory patterns between these conditions over low frequency and beta bands. This suggests that 
different oscillatory activities are associated with different phenotypes even in the same nucleus.  
Distinct circuit abnormalities might lend themselves to more targeted forms of DBS, including adaptive 
stimulation (Little et al. 2013). 
Low frequency activity  
Our results in patients with dystonia help address two questions: is prominent low frequency activity of 
the LFPs local to GPi or a basal ganglia circuit phenomenon, and is it specific to dystonia? Prominent 
low frequency activity of LFPs has been reported in dystonia in GPi (Liu et al. 2008; Moll et al. 2014; 
Sharott et al. 2008; Silberstein et al. 2003), and in STN (Neumann et al. 2012; Wang et al. 2016). Our 
data add to the evidence that low frequency activity is a basal ganglia circuit phenomenon rather than 
focal and this observation may help explain why DBS of both the STN and GPi can improve dystonia 
(Weinberger et al. 2011). However, is such low frequency activity specific to dystonia? In GPi low 
frequency activity is elevated in dystonic patients but not in patients with PD who are off their 
medication (Silberstein et al. 2003). A case report came to similar conclusions for STN (Neumann et al. 
2012), but a large case series concluded that there was no difference in low frequency activity in STN 
between patients with PD and dystonia (Wang et al. 2016). That said, this case series demonstrated a 
trend towards higher relative theta activity in the STN in dystonia than in PD (p = 0.0651; their 
supplementary figure 2).  
Our data point to a clear difference between the dystonic and untreated PD patients, both with spectral 
measures and LZC. However, this need not equate to a disease specific pattern of low frequency 
synchronisation in dystonia, as this activity in both the STN and GPi increases in those patients with PD 
who are treated and develop on-drug dyskinesia (Alonso-Frech et al. 2006; Chen et al. 2006b; Foffani et 
al. 2005; Rodriguez-Oroz et al. 2011; Silberstein et al. 2003; Silberstein et al. 2005; Weinberger et al. 
2011), and so it may not be disease pathology specific.  Others have linked elevated theta-alpha activity 
to mobile elements of dystonia (Barow et al. 2014), and as such it could be argued that exaggerated 
theta-alpha activity reflects a phenotype of mobile dystonia or dyskinesia, rather than being disease 
specific (Weinberger et al. 2011). 
Beta activity  
Prominent beta frequency band power has been consistently reported in the GPi and STN of PD patients 
withdrawn from their medication (Hammond et al. 2007). This was confirmed in the present PD cohort, 
but patients with dystonia, with the exception of one case, had no discrete or elevated beta power in STN. 
This is in line with some reports (Neumann et al. 2012; Weinberger et al. 2011), and was further borne 
out by the diminished LZC in the low beta band in PD patients, particularly when these were withdrawn 
from dopaminergic medications. Previously, the LZC of subthalamic 13-35 Hz oscillatory activity has 
been reported as correlating with clinical impairments in patients with PD (Chen et al. 2010).  
However, Wang et al. (2016) found no difference in beta activity in STN between patients with dystonia 
and PD. Nevertheless, ten out of the twelve patients reported by the latter group were receiving 
treatment with benzodiazepines, which can cause widespread increases of beta power and decreases of 
theta band power (Jensen et al. 2005; Yamadera et al. 1993). The Wang et al. (2016) study also differed 
in other respects, including its intra-operative nature so spectral differences might have conceivably 
been attenuated by the use of a general anesthetic an hour or two before the recordings, or by a 
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difference in the stun effect experienced immediately after microelectrode recordings and 
macroelectrode implantation. 
Our findings in case d8 highlight the particular importance of considering medication effects. This 
patient was taking clonazepam and aripiprazole. The latter is a partial agonist at D2 and 5-HT1A 
receptors and antagonist at 5-HT2A receptors (Jordan et al. 2002; Mailman et al. 2010; Shapiro et al. 
2003), which in some individuals can induce parkinsonism (Raj et al. 2004; Oommen et al. 2006) and in 
this individual was associated with a spectral pattern of LFPs in the STN that was similar to that seen in 
untreated patients with PD. Similar changes have been reported in the GPi in patients with dystonia 
treated with tetrabenazine (Kühn et al. 2008b), and in combination these data raise the possibility that 
excessive beta activity may be a hall mark of hypodopaminergic activity in the basal ganglia rather than 
of any specific disease pathology. This remains to be clarified. 
Gamma activity  
Patients with dystonia had greater subthalamic LFP power around 92 ± 8.6 Hz (mean ± SD) than 
patients with PD, whether the latter were on medication or withdrawn from medication. Gamma activity 
has previously been considered prokinetic (Brown. 2003), and the finding of elevated activity in the 
subthalamic LFP in dystonia would be in line with this. Peaks in the gamma range, albeit at slightly 
lower frequencies (60-95 Hz), have also been reported in the subthalamic LFP in some of patients with 
PD when on medication, and have been associated with the presence of dyskinesias (Fogelson et al. 
2005; Swann et al. 2016). Discrete peaks of local field potential activity at similar frequencies have been 
reported in motor cortex in a dyskinetic rodent model of PD (Halje et al. 2012) and in dyskinetic PD 
patients (Swann et al. 2016). Similar peaks have been reported in the human thalamus and globus 
pallidus in patients with dystonia, myoclonus and tremor, and so their mere presence may not be 
pathological (Kempf et al. 2009; Jenkinson et al. 2013). However, whether exaggeration of this rhythm 
relates to dyskinesias and dystonia remains a possibility, and the significance of the slight shift to higher 
frequencies in dystonia remains to be established. 
Dynamics of activity 
The LZC characterizes the complexity of a given signal by measuring the repeatable patterns in the 
signal, and is derived by counting the number of the new subsequences (Ziv and Lempel. 1977; Zhang et 
al. 2001; Aboy et al. 2006). The LZC reflects the rate of new patterns in the sequence, which is related 
to the randomness and predictability of the signal, and is also influenced by the level and distribution of 
the noise in the signal (Aboy et al. 2006). The LZC is low when the signal is regular and predictable, 
and it is high when the signal is random and less predictable. For example, the LZC decreases when the 
EEG signal becomes synchronised with high-amplitude slow waves (Andrillon et al. 2016), and is a 
robust measure reflecting the decrease of neural complexity of spontaneous EEG during general 
anesthesia (Schartner et al. 2015). This is able to accurately track the level of consciousness in patients 
and health subjects under anesthesia and during sleep (Zhang et al. 2001; Andrillon et al. 2016). In PD 
patients, resting state MEG signals show less complexity than in control subjects (Gomez et al. 2011). 
STN local field potentials in PD patients also have reduced complexity, and there is significant negative 
correlation between the complexity of these signals, assessed using LZC, and akinesia-rigidity (Chen et 
al. 2010). The LZC may therefore be considered a useful tool for capturing neural dynamics. 
Limitations and strengths of the present study 
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Recordings from the patient groups were derived from different centres which raises the possibility that 
there were subtle differences in the targeting. We were unable to explore this issue further due to the 
generally thick acquisition slices made during post-operative imaging in the patients with dystonia and 
the unavailability of some of the imaging in some of the archival patients. Targeting variance may 
increase the variance between subjects as LFP amplitude is dependent on the distance from the generator. 
Our spectral normalization and use of the LZC help address this issue. In Supplementary Methods we 
also include the spectral results when we average across all electrode contacts so as to further limit the 
effects of any potential small systematic variation in the targeting between the centres, although such 
averaging has the drawback that spatial resolution is limited and we can only ascribe those spectral 
findings to the STN area. Nevertheless, the differences between conditions in data from the broader STN 
area were similar to those presented in the main results. 
Interpretational ambiguity can be introduced when spectra are normalised by total spectral power in 
order to limit signal variance due to small differences in surgical targeting (Chen et al. 2010). Here, the 
results of analysis of z transformed spectral data were corroborated by the estimation of the LZC. This 
measure is not influenced by the amplitude scaling of the signal, but nevertheless is affected by the 
degree of beta activity, and negatively correlates with the latter (Chen et al. 2010). 
Conclusions 
In sum, the present data suggest that distinctive spectral patterns exist as basal ganglia circuit 
phenomena in PD and dystonia. It is the possibility that the same region can be involved in different 
patterns of circuit dysfunction that may explain the paradox whereby functional surgical approaches to 
the same target can improve different conditions (Brown and Eusebio. 2008).  
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TABLE 1. Clinical summary 
Case 
Age 
/Sex 
Diagnosis/main symptoms before operation Medication   
Pre-operative scales  
(dystonia: BFMDRS(MS,DS) /CDQ-24, off 
med; PD: UPDRS part-III, off/on med) 
Channel 
selection 
d1 21/M dystonia, primary generalised None 53 (43, 10) L12, R12 
d2 24/M dystonia, primary generalised None 50 (38, 12) L12, R01 
d3 44/F dystonia, primary generalised  None 58 (46, 12) L12, R12 
d4 74/F dystonia, neuroleptic induced cranial  None 24 (18, 6) L01, R12 
d5 25/M dystonia, cranial with blepharospasm None 28.5 (21.5, 7); CDQ-24: 90 L01, R01 
d6 65/M dystonia, cranial with blepharospasm None 5.5 (5.5, 0); CDQ-24: 46 L23, R23 
d7 52/F dystonia, cranial with blepharospasm None 4.5 (4.5, 0); CDQ-24: 44 L01, R12 
d8 67/F dystonia, cranial with blepharospasm 
Clonazepam and 
Aripiprazole 
12 (7, 5); CDQ-24: 62 L01, R12 
p1 56/F PD, bradykinesia 900mg LDED 26/7 L12, R12 
p2  70/M PD, freezing, gait 1100mg LDED 62/29 L12, R12 
p3 59/M PD, tremor 700mg LDED 28/5 L12, R23 
p4  60/M PD, freezing, bradykinesia 200mg LDED 25/13 L12, R12 
p5 60/F PD, bradykinesia, tremor, gait 1725mg LDED 63/7 L23, R12 
p6  32/M PD, left sided tremor 875mg LDED 52/13 R01 
p7 68/M PD, right sided tremor 475mg LDED 38/20 L23 
p8  58/M PD, bradykinesia, dyskinesia 270mg LDED 45/14 L23, R12 
p9 60/M PD, bradykinesia 600mg LDED 41/21 L12, R01 
p10 60/F PD, bradykinesia, gait 2000mg LDED 40/12 L01, R23 
p11 65/M PD, bradykinesia, rigidity, postural instability 1670mg LDED 23/7 L12, R01 
p12 38/M PD, tremor, mobility 370mg LDED 23/10 L12, R23 
d1-d8: dystonia cases. p1-p12: PD cases. LDED = L-DOPA daily equivalent dose. BFMDRS = Burke-Fahn-Marsden Dystonia Rating Scale. MS = Movement Score. 
DS = Disability Score. CDQ-24 = Craniocervical Dystonia Questionnaire. UPDRS = Unified Parkinson’s disease rating scale. Part – III: Motor Exam.   
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Figure 2. Group average normalised power spectra realigned to the peak frequency over 5-10 Hz in panel A, 11-32 Hz in 
panel B and 60-140 Hz in panel C. Results of serial two-sample, unpaired t-tests between the dystonia off medication 
(n=14 except n=12 for gamma band analysis) and PD group off (n=22) and on (n=22) medication and paired t-tests 
between PD on/off (both n=22) states are shown in D-F. LFPs were z-transformed before spectral analysis. The shadows 
in the respective colours denote ±1 standard deviations of the groups. As there were no clear gamma peaks in the 
selected channels of PD cases, 80Hz was taken as the centre frequency for realignment based on previous literature 
where fine-tuned gamma oscillations were usually found in 60-95 Hz (Kempf et al. 2009; Jenkinson et al. 2013).  
Figure 1. Group power spectra over 0-45 Hz (left) and 60-140 Hz (right) averaged across subjects with dystonia off 
medication (A and B, black line) and separately for case d8 on clonazepam and aripiprazole (A and B, green line); PD 
off levodopa (C and D, red line) and on levodopa (C and D, blue line). Dashed lines show individual spectra of all 
subjects in the respective conditions. Results of serial two-sample, unpaired t-tests between dystonia off medication 
and PD groups, one-sample t-tests between dystonia off medication and averaged case d8 on medication and paired 
t-tests between PD off and on (E and F).  LFPs were z-transformed before spectral analysis. Spectral resolution is 0.5 
Hz. Note ln (P) y axis scales in E and F.  
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Figure 3. Complexity analysis of bandpass filtered LFPs centred on the peak frequency in low frequency band (5-10 Hz), 
low beta band (11-20 Hz), high beta band (20-32 Hz) and gamma band (60-140Hz).  Significant differences were found 
in LZC among dystonia off, PD on and off conditions over low frequency (F(2, 55) = 21.4, p < 0.0001, ANOVA) , the low 
beta band (F(2, 55) = 104.4, p < 0.0001, ANOVA) and the gamma band F(2, 53)=316.3, p<0.0001, ANOVA). Note that 
two sides from one dystonic case (d6) were excluded for analysis in the gamma band due to artifacts.   *p  0.005, 
**p 0.001, post-hoc t-tests.  
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Supplementary figure 2. Group power spectra averaged across all bipolar channels in dystonia (A, black line, n=16 sides, 
48 channels; B, black line, n=14 sides, 42 channels), PD off medication (A and B, red line, n=22 sides, 66 channels) and 
PD on medication (A and B, blue line, n=22 sides, 66 channels). Results of t-tests between dystonia and PD on/off 
medication (C and D, black solid/dash lines) and paired t-tests between PD off and on medication states (C and D, red 
line). LFPs were z-transformed before spectral analysis. The shadows in the respective colours denote ± 1 standard 
deviations of the groups. Spectral resolution was 0.5 Hz. Note ln (P) axis scale in C and D. 
Supplementary figure 1.  Example time-frequency spectra of 50 seconds of LFPs over 3-45 Hz and 60-140Hz in dystonic 
case d4 off medication (A), dystonic case d8 on clonazepam and aripiprazole (B), PD case p5 off levodopa (C) and PD 
case p5 on levodopa (D). The window length for short-time Fourier transform was 2 seconds with 1.98 seconds overlap. 
Power amplitude shown in log value over the frequency of 3-45 Hz and 60-140 Hz respectively. 
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TABLE 1. Clinical summary 
Case 
Age 
/Sex 
Diagnosis/main symptoms before operation Medication   
Pre-operative scales  
(dystonia: BFMDRS(MS,DS) /CDQ-24, off med; PD: 
UPDRS part-III, off/on med) 
Channel 
selection 
d1 21/M dystonia, primary generalised None 53 (43, 10) L12, R12 
d2 24/M dystonia, primary generalised None 50 (38, 12) L12, R01 
d3 44/F dystonia, primary generalised  None 58 (46, 12) L12, R12 
d4 74/F dystonia, neuroleptic induced cranial  None 24 (18, 6) L01, R12 
d5 25/M dystonia, cranial with blepharospasm None 28.5 (21.5, 7); CDQ-24: 90 L01, R01 
d6 65/M dystonia, cranial with blepharospasm None 5.5 (5.5, 0); CDQ-24: 46 L23, R23 
d7 52/F dystonia, cranial with blepharospasm None 4.5 (4.5, 0); CDQ-24: 44 L01, R12 
d8 67/F dystonia, cranial with blepharospasm 
Clonazepam and 
Aripiprazole 
12 (7, 5); CDQ-24: 62 L01, R12 
p1 56/F PD, bradykinesia 900mg LDED 26/7 L12, R12 
p2  70/M PD, freezing, gait 1100mg LDED 62/29 L12, R12 
p3 59/M PD, tremor 700mg LDED 28/5 L12, R23 
p4  60/M PD, freezing, bradykinesia 200mg LDED 25/13 L12, R12 
p5 60/F PD, bradykinesia, tremor, gait 1725mg LDED 63/7 L23, R12 
p6  32/M PD, left sided tremor 875mg LDED 52/13 R01 
p7 68/M PD, right sided tremor 475mg LDED 38/20 L23 
p8  58/M PD, bradykinesia, dyskinesia 270mg LDED 45/14 L23, R12 
p9 60/M PD, bradykinesia 600mg LDED 41/21 L12, R01 
p10 60/F PD, bradykinesia, gait 2000mg LDED 40/12 L01, R23 
p11 65/M PD, bradykinesia, rigidity, postural instability 1670mg LDED 23/7 L12, R01 
p12 38/M PD, tremor, mobility 370mg LDED 23/10 L12, R23 
d1-d8: dystonia cases. p1-p12: PD cases. LDED = L-DOPA daily equivalent dose. BFMDRS = Burke-Fahn-Marsden Dystonia Rating Scale. MS = Movement Score. DS = Disability Score. 
CDQ-24 = Craniocervical Dystonia Questionnaire. UPDRS = Unified Parkinson’s disease rating scale. Part – III: Motor Exam.   
Table-1
Supplementary figure 1
Click here to download Supplementary Material: Supplementary figure 1 - stft of four cases comparison.eps
Supplementary figure 2
Click here to download Supplementary Material: Supplementary figure 2- psd zscored with ttest- achn -shadow.eps
